In The Spotlight


stock march30 Shares of ProQR Therapeutics N.V. (PRQR) have gained 22 percent over the last 10 trading days as the Company gears up to report findings from a planned three-month interim analysis of its trial, dubbed STELLAR, on March 31, 2020.

soliton march11 Aesthetic medical device company Soliton Inc. (SOLY) is all set to report results of a pivotal clinical trial evaluating its Rapid Acoustic Pulse, or RAP, device for the treatment of cellulite on March 21, 2020.

immunovant march10 Immunovant Inc. (IMVT), which began trading on the NASDAQ on December 19, 2019, has since gained nearly 13 percent.

akero march09 Akero Therapeutics Inc. (AKRO), which completed its IPO last June, has since gained more than 30 percent and trades around $24.

imraipo march05 Boston, Massachusetts-based Imara Inc. is slated to debut on the Nasdaq Global Select Market, under the symbol 'IMRA', on March 12, 2020. Imara is a clinical-stage biopharmaceutical company developing novel therapeutics to treat patients with rare inherited genetic disorders of hemoglobin, known as...

syndax march06 Syndax Pharmaceuticals Inc. (SNDX), a clinical-stage biopharmaceutical company developing cancer therapies, has a number of data readouts lined up for this year. The Company's stock has gained nearly 28 percent in just 5 trading days.

lipocine march05 Lipocine Inc.'s (LPCN) TLANDO, an oral testosterone product candidate, is back at the FDA altar again, with a decision date now set for August 28, 2020.

Shares of Daxor Corp (DXR) are up over 70% in Tuesday's trading after the Company announced an active engagement with both hospitals and government agencies in the military and civilian sectors regarding the use of its BVA-100 blood volume analyzer to stem COVID-19 deaths.

vaxart feb25 Shares of Vaxart Inc. (VXRT) have gained an impressive 265 percent so far this year on hopes of a vaccine for the novel coronavirus.

soligenix feb24 Soligenix Inc. (SNGX), a late-stage biopharmaceutical company developing products to treat rare diseases, has multiple potential value drivers, making the stock worth watching.

biotechipo feb04 The Philadelphia-based Passage Bio is slated to debut on the Nasdaq Global Market under the symbol "PASG" on February 28, 2020. Passage Bio is a genetic medicines company developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment...

infusystem feb20 Shares of InfuSystem Holdings Inc. (INFU) have been hitting new highs, as the Company continues to gain market share in its oncology business and sees continued growth in its pain management and infusion products markets.

pharma sept27 19feb20 Evelo Biosciences Inc. (EVLO), which touched $6.82 in early trading, up 23% from the previous day's close, is one of the top gainers of the day as the Company continues to build on the momentum, with multiple clinical readouts planned across its inflammation and oncology portfolio this year.

pharma 050517 19feb20 Shares of Rubius Therapeutics Inc. (RUBY) have lost over 57 percent of their value from the yearly high of $20.04, recorded on April 5, 2019, and trade around $8.

ipo dec23 Redwood City, California-based Revolution Medicines is slated to debut on the Nasdaq Global Select Market, under the symbol 'RVMD', on February 12, 2020.

Follow RTT